Edgestream Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Edgestream Partners’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-65,230	Closed	-$822K	–	875
2025 Q4	$822K	Buy	+65,230	New	+$746K	0.02%	730

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Edgestream Partners's AMRX Position: Q1 2026 in Review

Edgestream Partners sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 65,230 shares — an estimated $822K sold.

Edgestream Partners first reported a position in AMRX in Q4 2025 and held it in 1 quarter. The position peaked at $822K in Q4 2025. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

Edgestream Partners reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Edgestream Partners sold 65,230 Amneal Pharmaceuticals shares in Q1 2026, an estimated $822K.
Edgestream Partners first reported a position in Amneal Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Edgestream Partners's Amneal Pharmaceuticals position peaked at $822K in Q4 2025.
316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.